Actively Recruiting
Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke
Led by Zhongming Qiu · Updated on 2025-12-31
1000
Participants Needed
1
Research Sites
114 weeks
Total Duration
On this page
Sponsors
Z
Zhongming Qiu
Lead Sponsor
X
Xiangtan Central Hospital (The Affiliated Hospital of Hunan University)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Since 2015, many randomized trials have shown that endovascular thrombectomy improve functional outcomes in acute ischemic stroke patients with large vessel occlusion. Recently, five randomized controlled trials (ANGEL-ASPECT \[Endovascular Therapy in Acute Anterior Circulation Large Vessel Occlusive Patients with a Large Infarct Core\], LASTE \[LArge Stroke Therapy Evaluation\], RESCUE-Japan LIMIT \[The Recovery by Endovascular Salvage for Cerebral Ultra-Acute Embolism-Japan Large Ischemic Core Trial\], SELECT 2 \[Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke\], and TENSION \[The Efficacy and Safety of Thrombectomy in Stroke with extended lesion and extended time window\]) demonstrated the efficacy and safety of thrombectomy for large infarct patients (defined as Alberta Stroke Program Early Computed Tomography Score \[ASPECTS\] ≥3 or infarct core \<100ml). Patients with extra-large infarct core (ASPECTS score of 2 or less) were excluded from these trials. Therefore, the efficacy of endovascular thrombectomy in patients with extra-large ischemic burden has not been well studied. The XL STROKE registry is aiming to investigate the clinical outcomes and safety of mechanical thrombectomy in acute extra-large ischemic stroke.
CONDITIONS
Official Title
Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Acute ischemic stroke onset within 24 hours of last known well
- Signed informed consent obtained from patient or representative
- Confirmed blockage of internal carotid artery or middle cerebral artery M1 or M2 segments by imaging
- Baseline ASPECTS score of 0 to 2 or ischemic core volume of 85ml or greater based on imaging
You will not qualify if you...
- Evidence of acute intracranial hemorrhage on CT or MRI
- Imaging signs of mass effect such as ventricular compression, midline shift, or brain herniation
- Pregnant women or women of childbearing potential with positive pregnancy test
- History of bleeding disorders, severe heart, liver, or kidney disease, or sepsis
- Terminal illness with life expectancy under 6 months
- Participation in another clinical treatment trial
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xiangtan Central Hospital
Xiangtan, Hunan, China, 421001
Actively Recruiting
Research Team
Z
Zhongming Qiu
CONTACT
T
Thanh N. Nguyen
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here